Skip to content

Immediate Therapeutic Effects of Diquafosol and Rebamipide in Dry Eye Disease

Comparison of Immediate Therapeutic Effects of 3% Diquafosol and 2% Rebamipide in Dry Eye Disease

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07297316
Enrollment
30
Registered
2025-12-22
Start date
2022-10-03
Completion date
2024-08-30
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Disease (DED)

Brief summary

This study compares the immediate therapeutic and mucin-secreting effects 30 minutes after instillation of 3% diquafosol and 2% rebamipide in dry eye disease.

Interventions

DRUG3% diquafosol (right eye) and 2% rebamipide (left eye)

3% diquafosol was instilled in the right eye and 2% rebamipide in the left eye.

DRUG2% rebamipide (right eye) and 3% diquafosol (left eye)

2% rebamipide was instilled in the right eye and 3% diquafosol in the left eye.

Sponsors

Kukje Pharma
CollaboratorOTHER
Korea University Anam Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

This is a paired-eye design study, where patients received 3% diquafosol in one eye and 2% rebamipide in the contralateral eye.

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients 19 years or older * complaint of at least one dry eye symmptom and tear breakup time \< 7 seconds

Exclusion criteria

* Sjogren's syndrome * prescription history of systemic steroids or immunosuppressants * prior ocular surgery within six months of enrollment * treatment with diquafosol or rebamipide eye drops within 2 weeks of enrollment * treatment with punctal plug within 1 month of enrollment * intraocular pressure exceeding 25mmHg * usage of contact lens during the study * active ocular infection * pregnancy or breast-feeding

Design outcomes

Primary

MeasureTime frameDescription
corneal sensitivity (esthesiometer)Before instillation of eyedrops, and 30 minutes after instillation of eyedropsUnit: mm
tear meniscus height (TMH)Before instillation of eyedrops, and 30 minutes after instillation of eyedropsUnit: mm
lipid layer thickenss (LLT)Before instillation of eyedrops, and 30 minutes after instillation of eyedropsUnit: nm
visual analog scale (VAS) scoreBefore instillation of eyedrops, and 30 minutes after instillation of eyedropsUnit: points
tear breakup time (TBUT)Before instillation of eyedrops, and 30 minutes after instillation of eyedropsUnit: Seconds
ocular staining score (OSS)Before instillation of eyedrops, and 30 minutes after instillation of eyedropsNational Eye Institute Scale, 0-15

Secondary

MeasureTime frameDescription
tear MUC5AC concentrationBefore instillation of eyedrops, and 30 minutes after instillation of eyedropsmeasured using enzyme-linked immunosorbent assay (ELISA)
tear MUC1 concentrationBefore instillation of eyedrops, and 30 minutes after instillation of eyedropsmeasured using enzyme-linked immunosorbent assay (ELISA)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026